Vectura Group PLC (VEC.L)
1 Dec 2015
* Half year pretax loss 5 mln stg vs 6.2 mln stg loss year ago
* US FDA approves new dual combination bronchodilator Utibron Neohaler and stand-alone monotherapy Seebri Neohaler for patients with chronic obstructive pulmonary disease
* Announces successful pre-ind meeting with US FDA regarding vr647
June 24 Respiratory drugs specialist Vectura Group Plc appointed AstraZeneca executive James Ward-Lilley as chief executive officer effective Oct. 1.
* Announces appointment of James Ward-Lilley as CEO and executive director. James will succeed Dr Chris Blackwell who, as previously announced, leaves Vectura at end of June 2015
* Vectura Group (UK, B01D1K4) will be added to FTSE 250 index